C12N9/52

Truncated and modified serratiopeptidase and polynucleotides encoding the same

A truncated and modified Serratiopeptidase or a variant thereof, and polynucleotides encoding the same. The truncated and modified Serratiopeptidase may have an amino acid sequence including amino acids 1 to 344, and amino acids 1 to 380 of SEQ ID NO: 1. The truncated and modified Serratiopeptidase may further include a first Cysteine (C) residue at a N-terminus of the truncated and modified Serratiopeptidase, substituted for at least one of Alanine 8 and Leucine 12 of SEQ ID NO: 1; and a second Cysteine residue at a C-terminus of the truncated and modified Serratiopeptidase, substituted for at least one of Valine 339 and Arginine 302 of SEQ ID NO: 1. The first and the second Cysteine residues may be adapted to form at least one disulfide bond including at least one of C8-C339, and C12-C302 disulfide bonds between the N-terminus and the C-terminus of the truncated and modified Serratiopeptidase.

Protein modification of living cells using sortase

Non-genetically engineered mammalian cells modified by sortase-mediated conjugation of an agent thereto are provided. Methods of conjugating agents to non-genetically engineered mammalian cells using sortase are provided. Methods of using the cells, e.g., for diagnostic and/or therapeutic purposes, are provided.

Protein modification of living cells using sortase

Non-genetically engineered mammalian cells modified by sortase-mediated conjugation of an agent thereto are provided. Methods of conjugating agents to non-genetically engineered mammalian cells using sortase are provided. Methods of using the cells, e.g., for diagnostic and/or therapeutic purposes, are provided.

Antibodies for prevention, treatment and diagnosis of <i>P. gingivalis </i>infection

Disclosed are P. gingivalis antibodies raised against a chimeric or fusion protein, wherein the chimeric or fusion protein comprises a first peptide joined directly or through a linker to a second peptide or polypeptide, wherein (A) the first peptide comprises a region of a P. gingivalis trypsin-like enzyme and (B) the second peptide or polypeptide comprises an adhesin domain of P. gingivalis.

Antibodies for prevention, treatment and diagnosis of <i>P. gingivalis </i>infection

Disclosed are P. gingivalis antibodies raised against a chimeric or fusion protein, wherein the chimeric or fusion protein comprises a first peptide joined directly or through a linker to a second peptide or polypeptide, wherein (A) the first peptide comprises a region of a P. gingivalis trypsin-like enzyme and (B) the second peptide or polypeptide comprises an adhesin domain of P. gingivalis.

Sortase

Reported herein is a sortase comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 11 and that comprises the mutations D101S and K137S.

Sortase

Reported herein is a sortase comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 11 and that comprises the mutations D101S and K137S.

LIGASE FUSION PROTEINS AND APPLICATION THEREOF
20230097252 · 2023-03-30 ·

The present disclosure relates to the field of biotechnology. In particular, provided are a ligase fusion protein and an immobilized ligase comprising the same. Also provided is use of the ligase fusion protein or the immobilized ligase in the preparation of conjugates. Further provided is a process for the preparation of conjugates using a ligase or a ligase unit.

LIGASE FUSION PROTEINS AND APPLICATION THEREOF
20230097252 · 2023-03-30 ·

The present disclosure relates to the field of biotechnology. In particular, provided are a ligase fusion protein and an immobilized ligase comprising the same. Also provided is use of the ligase fusion protein or the immobilized ligase in the preparation of conjugates. Further provided is a process for the preparation of conjugates using a ligase or a ligase unit.